针对NFAT2,通过曼尼迪平因逆转P-gp介导的对帕克利塔塞尔的多药性耐药性
Jian Zhou1, Nan Wang1, Yu-Kang Lin1
1State Key Laboratory of Traditional Chinese Medicine Syndrome, Chinese Medicine Guangdong Laboratory (Hengqin Laboratory), The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Cancers
|October 29, 2025
概括
曼尼迪平 (MA) 通过抑制P-glycoprotein (P-gp) 流量和通过NFAT2调节信号,有效地逆转癌症中的多药性耐药性 (MDR). 这表明MA是一种潜在的治疗剂,可以克服化疗失败.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 癌症中的多药性耐药性 (MDR),由P-glycoprotein (P-gp) 驱动,显著限制化疗的疗效.
- 在瘤学中,P-gp介导的药物外流是治疗失败和患者治疗结果差的主要原因.
研究的目的:
- 调查曼尼迪平 (MA),一种通道阻断剂,作为P-gp介导的MDR的调节剂.
- 探索MA的机制,包括信号传递和激活T细胞2 (NFAT2) 的核因子.
主要方法:
- 在体外和体外使用了抗帕克利塔塞尔 (PTX) 的癌细胞系 (过度表达ABCB1).
- 评估了MA的抗MDR作用和机制,使用siRNA用于NFAT2.
- 测量了细胞内药物积累,P-gp ATPase活性,细胞内水平和NFAT2表达.
主要成果:
- 在非有毒度下,MA使耐性结直肠 (HCT-8/T) 和肺 (A549/T) 癌细胞对PTX敏感,降低IC50的1328倍.
- MA抑制了P-gp流量活动,增加了细胞内多克索鲁比辛和Flutax-2的积累 (2.3和3.1倍).
- 马减少了细胞内 (52%),并降低了NFAT2,同时与PTX协同抑制体内瘤生长 (68%的减少).
结论:
- 曼尼迪平作为一种新型NFAT2抑制剂,可以克服P-gp介导的MDR.
- 通过调节信号通路,MA可以逆转MDR.
- 这些发现支持对曼尼迪平用于克服癌症治疗中耐药性的进一步临床研究.
相关概念视频
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Carrier-Mediated Transport
1.1K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
429
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
429
Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K


